Floatz logo

Nivolumab

Vaginal Carcinoma

National Cancer Institute (NCI)monoclonal_antibodyPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Vaginal Carcinoma cohort.

Asset / SponsorPhaseRating
Durvalumab
M.D. Anderson Cancer Center
Phase 2B
Dna Plasmid-Encoding Interleukin-12/Hpv Dna Plasmids Therapeutic Vaccine Medi0457
M.D. Anderson Cancer Center
Phase 2CCC
Ipilimumab
National Cancer Institute (NCI)
Phase 2CCC
Plasmid Encoded Il-12
M.D. Anderson Cancer Center
Phase 2CCC
Carboplatin
Case Comprehensive Cancer Center
Phase 1CCC

View all 18 →

Same molecule, other indications

Nivolumab is also rated in:

Recurrent Non-Hodgkin LymphomaDormant
BBB
Indicative ·
74 / 100
View asset →
renal carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
metastatic melanomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →